Editing Sarcoma (section)

== Research ==
Treatment of sarcoma, especially when the sarcoma has spread, or "metastasized", often requires chemotherapy but existing chemotherapeutic medicines are associated with significant toxicities and are not highly effective in killing cancer cells.<ref name=":2" /> Therefore, research to identify new medications to treat sarcoma is being conducted {{as of|2023|alt=as of 2019}}.<ref name=":2" /> One new type of therapy still under investigation is the use of [[cancer immunotherapy]] (e.g., immune checkpoint inhibitors like anti-PD1, anti-PDL1, and anti-CTLA4 agents) to treat sarcomas.<ref name=":10">{{cite journal | vauthors = Thanindratarn P, Dean DC, Nelson SD, Hornicek FJ, Duan Z | title = Advances in immune checkpoint inhibitors for bone sarcoma therapy | journal = Journal of Bone Oncology | volume = 15 | pages = 100221 | date = April 2019 | pmid = 30775238 | pmc = 6365405 | doi = 10.1016/j.jbo.2019.100221 | doi-access = free }}</ref> These drugs are not yet FDA- or other regulator-approved treatment, except PDL1 inhibitor atezolizumab for the ultra-rate diagnosis of alveolar soft part sarcoma.<ref name=":10" /><ref>{{Cite journal |last1=Chen |first1=Alice P. |last2=Sharon |first2=Elad |last3=O'Sullivan-Coyne |first3=Geraldine |last4=Moore |first4=Nancy |last5=Foster |first5=Jared C. |last6=Hu |first6=James S. |last7=Van Tine |first7=Brian A. |last8=Conley |first8=Anthony P. |last9=Read |first9=William L. |last10=Riedel |first10=Richard F. |last11=Burgess |first11=Melissa A. |last12=Glod |first12=John |last13=Davis |first13=Elizabeth J. |last14=Merriam |first14=Priscilla |last15=Naqash |first15=Abdul R. |date=2023-09-07 |title=Atezolizumab for Advanced Alveolar Soft Part Sarcoma |journal=The New England Journal of Medicine |volume=389 |issue=10 |pages=911–921 |doi=10.1056/NEJMoa2303383 |issn=1533-4406 |pmid=37672694|pmc=10729808 }}</ref> Other strategies, such as small-molecule [[targeted therapy]], biologic agents (e.g., [[small interfering RNA]] molecules), and [[nanoparticle]]-directed therapy, also are under active investigated.<ref name=":2" />

Research to understand the specific genetic and molecular factors that cause sarcoma to develop is underway.<ref name=":2" /> This could allow for the design of new targeted therapies and allow physicians to more accurately predict a patient's prognosis.<ref name=":2" />